The search for meaningful medicines
Sumitomo Pharma Oncology (SMP Oncology) is united in the search for clinically meaningful medicines and powered by purposeful science. Explore our pipeline to learn more about our advancements in translational research.
- The pipeline represented here may not be comprehensive of all SMP Oncology’s investigative and clinical activities
- Additional, ongoing clinical trials conducted in Japan by Sumitomo Pharma Co., Ltd., are not listed on this website. For information about these trials, please visit www.sumitomo-pharma.co.jp/rd/clinical/pipeline
- All development candidates are investigational agents, and their safety and efficacy have not been established. There is no guarantee that any of these agents will receive health authority approval or become commercially available in any country for the uses being investigated
- For additional information on clinical studies, including studies that are actively recruiting, please see www.clinicaltrials.gov or contact us
AML=acute myeloid leukemia; ALL=acute lymphocytic leukemia; CDK=cyclin-dependent kinase; EBP=emopamil-binding protein; PKM2=pyruvate kinase M2 isoform.
Discover the science behind the compound
Each of our compounds represents the culmination of global expertise and persistent scientific inquiry. To explore the science behind our pipeline, see our Clinical Programs page.Take a closer look